FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4384408096> ?p ?o ?g. }

• W4384408096 endingPage "1604" @default.
• W4384408096 startingPage "1595" @default.
• W4384408096 abstract "Use of sodium glucose cotransporter 2 inhibitors (SGLT2i) was associated with a reduction in atrial fibrillation hospitalizations. Therefore, we aim to evaluate the effects of SGLT2i on atrial tachy-arrhythmias (ATA) in patients with cardiac implantable electronic devices (CIEDs).All 13 888 consecutive patients implanted with a CIED in two tertiary medical centers were enrolled. Treatment with SGLT2i was assessed as a time dependent variable. The primary endpoint was the total number of ATA. Secondary endpoints included total number of ventricular tachy-arrhythmias (VTA), ATA and VTA, and death. All events were independently adjudicated blinded to the treatment. Multivariable propensity score modeling was performed.During a total follow-up of 24 442 patient years there were 62 725 ATA and 10 324 VTA events. Use of SGLT2i (N = 696) was independently associated with a significant 22% reduction in the risk of ATA (hazard ratio [HR] = 0.78 [95% confidence interval {CI} = 0.70-0.87]; p < .001); 22% reduction in the risk of ATA/VTA (HR = 0.78 [95% CI = 0.71-0.85]; p < .001); and with a 35% reduction in the risk of all-cause mortality (HR = 0.65 [95% CI = 0.45-0.92]; p = .015), but was not significantly associated with VTA risk (HR = 0.92 [95% CI = 0.80-1.06]; p = .26). SGLT2i were associated with a lower ATA burden in heart failure (HF) patients but not among diabetes patients (HF: HR = 0.68, 95% CI = 0.58-0.80, p < .001 vs. Diabetes: HR = 0.95, 95% CI = 0.86-1.05, p = .29; p < .001 for interaction between SGLT2i indication and ATA burden).Our real world findings suggest that in CIED HF patients, those with SGLT2i had a pronounced reduction in ATA burden and all-cause mortality when compared with those not on SGLT2i." @default.
• W4384408096 created "2023-07-16" @default.
• W4384408096 creator A5005698298 @default.
• W4384408096 creator A5005973866 @default.
• W4384408096 creator A5006294179 @default.
• W4384408096 creator A5007803409 @default.
• W4384408096 creator A5008613276 @default.
• W4384408096 creator A5020045335 @default.
• W4384408096 creator A5026922540 @default.
• W4384408096 creator A5034289475 @default.
• W4384408096 creator A5039533444 @default.
• W4384408096 creator A5064083006 @default.
• W4384408096 creator A5070015764 @default.
• W4384408096 creator A5076919385 @default.
• W4384408096 creator A5077082770 @default.
• W4384408096 creator A5082459061 @default.
• W4384408096 creator A5087690567 @default.
• W4384408096 creator A5092476488 @default.
• W4384408096 creator A5092476489 @default.
• W4384408096 date "2023-07-15" @default.
• W4384408096 modified "2023-09-25" @default.
• W4384408096 title "Effect of sodium glucose cotransporter 2 inhibitors on atrial tachy‐arrhythmia burden in patients with cardiac implantable electronic devices" @default.
• W4384408096 cites W2068225029 @default.
• W4384408096 cites W2078812006 @default.
• W4384408096 cites W2102014314 @default.
• W4384408096 cites W2102904190 @default.
• W4384408096 cites W2126896570 @default.
• W4384408096 cites W2128317502 @default.
• W4384408096 cites W2161984704 @default.
• W4384408096 cites W2261821782 @default.
• W4384408096 cites W2528468257 @default.
• W4384408096 cites W2565298490 @default.
• W4384408096 cites W2598092556 @default.
• W4384408096 cites W2626446274 @default.
• W4384408096 cites W2745253866 @default.
• W4384408096 cites W2781808713 @default.
• W4384408096 cites W2799739525 @default.
• W4384408096 cites W2807107286 @default.
• W4384408096 cites W2809217674 @default.
• W4384408096 cites W2900413769 @default.
• W4384408096 cites W2903431537 @default.
• W4384408096 cites W2974260792 @default.
• W4384408096 cites W2984471300 @default.
• W4384408096 cites W2995061256 @default.
• W4384408096 cites W3004319546 @default.
• W4384408096 cites W3034172966 @default.
• W4384408096 cites W3036816724 @default.
• W4384408096 cites W3080459529 @default.
• W4384408096 cites W3081830235 @default.
• W4384408096 cites W3091750031 @default.
• W4384408096 cites W3136045622 @default.
• W4384408096 cites W3159400876 @default.
• W4384408096 cites W3164567905 @default.
• W4384408096 cites W3193297191 @default.
• W4384408096 cites W3193981514 @default.
• W4384408096 cites W3210475044 @default.
• W4384408096 doi "https://doi.org/10.1111/jce.15996" @default.
• W4384408096 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37453072" @default.
• W4384408096 hasPublicationYear "2023" @default.
• W4384408096 type Work @default.
• W4384408096 citedByCount "0" @default.
• W4384408096 crossrefType "journal-article" @default.
• W4384408096 hasAuthorship W4384408096A5005698298 @default.
• W4384408096 hasAuthorship W4384408096A5005973866 @default.
• W4384408096 hasAuthorship W4384408096A5006294179 @default.
• W4384408096 hasAuthorship W4384408096A5007803409 @default.
• W4384408096 hasAuthorship W4384408096A5008613276 @default.
• W4384408096 hasAuthorship W4384408096A5020045335 @default.
• W4384408096 hasAuthorship W4384408096A5026922540 @default.
• W4384408096 hasAuthorship W4384408096A5034289475 @default.
• W4384408096 hasAuthorship W4384408096A5039533444 @default.
• W4384408096 hasAuthorship W4384408096A5064083006 @default.
• W4384408096 hasAuthorship W4384408096A5070015764 @default.
• W4384408096 hasAuthorship W4384408096A5076919385 @default.
• W4384408096 hasAuthorship W4384408096A5077082770 @default.
• W4384408096 hasAuthorship W4384408096A5082459061 @default.
• W4384408096 hasAuthorship W4384408096A5087690567 @default.
• W4384408096 hasAuthorship W4384408096A5092476488 @default.
• W4384408096 hasAuthorship W4384408096A5092476489 @default.
• W4384408096 hasConcept C126322002 @default.
• W4384408096 hasConcept C134018914 @default.
• W4384408096 hasConcept C164705383 @default.
• W4384408096 hasConcept C168563851 @default.
• W4384408096 hasConcept C203092338 @default.
• W4384408096 hasConcept C207103383 @default.
• W4384408096 hasConcept C2778198053 @default.
• W4384408096 hasConcept C2779161974 @default.
• W4384408096 hasConcept C44249647 @default.
• W4384408096 hasConcept C50382708 @default.
• W4384408096 hasConcept C555293320 @default.
• W4384408096 hasConcept C71924100 @default.
• W4384408096 hasConceptScore W4384408096C126322002 @default.
• W4384408096 hasConceptScore W4384408096C134018914 @default.
• W4384408096 hasConceptScore W4384408096C164705383 @default.
• W4384408096 hasConceptScore W4384408096C168563851 @default.
• W4384408096 hasConceptScore W4384408096C203092338 @default.
• W4384408096 hasConceptScore W4384408096C207103383 @default.
• W4384408096 hasConceptScore W4384408096C2778198053 @default.

• next